Bachem announced on July 21, 2026, that it has signed an agreement to supply large volumes of peptides, leading to a greenfield project investment exceeding CHF 500 million in Sisslerfeld. The strategic collaboration includes pre-payments and long-term commitments, with commercial production…
Bachem SIX: BANB announced on July 21, 2026, that it has signed an agreement to supply large volumes of peptides. This commitment triggers a greenfield project in Sisslerfeld, Switzerland, with an investment exceeding CHF 500 million. The strategic collaboration includes pre-payments and long-term commitments. Commercial production at the new site in Sisslerfeld is expected to start in 2030. The collaboration partners have agreed not to disclose any further details.
Bachem disclosed that it will invest more than CHF 500 million in the greenfield project located in Sisslerfeld. The investment is part of a strategic collaboration that covers pre-payments and long-term commitments from its partner. The agreement is designed to ensure a reliable supply of large volumes of peptides. The partners have mutually decided not to reveal additional information about the terms of the deal. The expected date for the start of commercial production at the new facility is 2030.
This investment follows Bachem's broader strategy to expand capacity across its entire manufacturing network. The company is implementing a program that includes facilities designed for high-volume production of both peptides and oligonucleotides. By doing so, Bachem aims to strengthen its position as a leading global partner for TIDES, a term encompassing therapeutic peptides, oligonucleotides, and related molecules. The new Sisslerfeld site is a key component of this network expansion.
The CEO's remarks highlight the strategic importance of the Sisslerfeld project. The facility will allow Bachem to better serve its customers by providing a dedicated high-volume production site. The long-term nature of the agreement provides planning security for Bachem, enabling the company to allocate resources effectively across its global network. This includes balancing investments between new sites like Sisslerfeld and existing facilities such as those in Bubendorf, Vionnaz, Vista, Torrance, and St. Helens.
Bachem operates as a global network of manufacturing sites. The network currently includes Bubendorf in Switzerland, Sisslerfeld in Switzerland, Vionnaz in Switzerland, Vista in the United States, Torrance in the United States, and St. Helens in the United Kingdom. The new facility in Sisslerfeld will add significant production capacity to this network. Bachem is implementing a program to expand capacity across its entire network, including facilities designed for high-volume production of peptides and oligonucleotides. This expansion is intended to strengthen Bachem’s position as a leading global partner for TIDES.
The company's global footprint allows it to serve pharmaceutical and biotechnology companies worldwide. Each site has specific capabilities, but together they form an integrated manufacturing network. The investment in Sisslerfeld represents a major addition, particularly for large-scale peptide production. Bachem's strategy involves coordinating investments across all sites to ensure balanced growth and operational efficiency. The new facility will comply with regulatory standards and support both clinical and commercial supply.
Bachem is a leading, innovation-driven company that specializes in the development and manufacture of peptides and oligonucleotides. The company has over 50 years of experience and expertise in this field. It provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies globally. Bachem offers a comprehensive range of services, including custom synthesis, catalog peptides, and commercial manufacturing of peptide APIs, amino acid derivatives, cosmetic peptides, and peptides for medical devices. For oligonucleotides, Bachem provides clinical development and commercial manufacturing services.
Related reading: Bachem Plans 2030 Commercial Production at Sisslerfeld Peptide Site, Samsung Biologics to Acquire PolyPeptide for $1.8 Billion, Expanding into GLP-1 Market, Samsung Biologics Expands Peptide Capacity to Lead Obesity Drug CDMO, Samsung Biologics Offers $1.8 Billion for Swiss Peptide CDMO PolyPeptide.